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Introduction 
Endoscopic sinus surgery (ESS) has become the most com-
mon technique for the surgical management of chronic rhinosi-
nusitis [1]. Visualization of the surgical field is a major concern 
during ESS, as surgical bleeding is an important cause of various 
complications, including vessel or nerve damages and cerebro-
spinal fluid leakage [2]. Moreover, improved visualization of the 
surgical field may bring about not only fewer complications, but 
also a reduced surgical time, faster postoperative recovery, and a 
reduced relapse rate [3,4].
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Background: In endoscopic sinus surgery, visualization of the surgical field is a major concern, as surgical bleeding is the 
cause of many complications. The purpose of this study was to compare the effects of dexmedetomidine and remifentanil 
on the visualization of the surgical field in endoscopic sinus surgery.
Methods: Forty-three patients were prospectively enrolled and randomly allocated to the dexmedetomidine or remifent-
anil group and general anesthesia was induced and maintained using a propofol target-controlled infusion. In the dexme-
detomidine group, dexmedetomidine was loaded for 5 min and a continuous infusion was administered. In the remifent-
anil group, a remifentanil target-controlled infusion was used. After completion of the operation, the satisfaction with the 
visualization of the surgical field was assessed on a numeric rating scale, from 0 (= worst) to 10 (= best). The mean blood 
pressure, heart rate, recovery profiles, and postoperative pain score were recorded.
Results: Satisfaction score for visualization by numeric rating scale was not significantly different between the two groups 
(P = 0.95). There were no differences in the mean blood pressure and heart rate. The extubation time was significantly 
shorter in the dexmedetomidine group (8.4 ± 1.8 min) than in the remifentanil group (11.9 ± 5.4 min) (P = 0.04). Except 
for the extubation time, the recovery profiles of the two groups were comparable.
Conclusions: Continuous infusions of dexmedetomidine provide a similar visualization of the surgical field and hemo-
dynamic stability as remifentanil target-controlled infusions in patients undergoing endoscopic sinus surgery. 
Key Words: Blood loss, Dexmedetomidine, Remifentanil, Sinusitis.
Efficacy of intraoperative 
dexmedetomidine infusion on 
visualization of the surgical field in 
endoscopic sinus surgery
Hyunzu Kim1, Sang-Hee Ha2, Chang-Hoon Kim3, Sang-Hoon Lee1, and 
Seung-Ho Choi2
Department of Anesthesiology and Pain Medicine, 1Kangdong Sacred Heart Hospital, Hallym University College of 
Medicine, 2Yonsei University College of Medicine, 3Department of Otorhinolaryngology, Medical Research Center, 
Yonsei University College of Medicine, Seoul, Korea 
CC  This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright ⓒ the Korean Society of Anesthesiologists, 2015 Online access in http://ekja.org
pISSN 2005-6419  •  eISSN 2005-7563
Korean Journal of Anesthesiology
KJA
Corresponding author: Seung-Ho Choi, M.D., Ph.D.
Department of Anesthesiology and Pain Medicine, Yonsei University 
College of Medicine, 50-1, Yonsei-ro, Seodaemun-gu, Seoul 03722, 
Korea
Tel: 82-2-2228-2420, Fax: 82-2-2227-7897
E-mail: csho99@yuhs.ac
Received: April 8, 2015.  
Revised: 1st, May 26, 2015; 2nd, June 29, 2015; 3rd, July 3, 2015.  
Accepted: July 5, 2015.
Korean J Anesthesiol 2015 October 68(5): 449-454 
http://dx.doi.org/10.4097/kjae.2015.68.5.449 
450 Online access in http://ekja.org
VOL. 68, NO. 5, OctOber 2015 Dexmedetomidine on visualization
The nasal cavity is a limited space normally available through 
a nostril, and the surgeon can only use one hand to perform the 
work, as the other one holds the scope. The techniques used to 
control bleeding in other parts of the body cannot be used for 
surgeries of the nasal cavities and paranasal sinuses [5]. Many 
studies have ascertained the efficacy of specialized methods for 
reducing surgical bleeding during ESS. Above all, Guven et al. [6] 
found a lower heart rate (HR) and mean blood pressure (MBP) 
in patients receiving dexmedetomidine, and suggested that the 
administration of the drug may cause less bleeding. 
The purpose of this prospective randomized controlled study 
was to compare the effects of intravenous dexmedetomidine as 
an adjuvant agent for propofol anesthesia and propofol-remifen-
tanil TCI on the visualization of the surgical field, hemodynamic 
changes, and recovery profiles in the recovery period from gen-
eral anesthesia in patients undergoing ESS. 
Materials and Methods
This study was approved by the University Hospital Ethic 
Committee and was registered at ClinicalTrials.gov. Written 
informed consent was obtained from all patients. Forty-three 
patients aged 20−70 years old of American Society of Anesthesi-
ologists physical status I and II who had been scheduled to un-
dergo endoscopic sinus surgery, were prospectively enrolled in 
this study. The patients with a body mass index of 30 or higher, 
with congestive heart failure, a bradycardia rate under 50 per 
minute, first degree or more atrioventricular block, uncontrolled 
high blood pressure, clotting disorders, allergic fungal sinus-
itis or infection with multiple nasal polyps, and those who did 
not understand the meaning of the study or could not read the 
agreement, were excluded from the study. The patients’ preop-
erative computed tomography scores (Lund-Mackay Computed 
Tomography Staging System) were evaluated and recorded [7].
None of the patients were premedicated upon arrival in the 
operating room. The routine anesthesia monitoring consisted 
of an electrocardiogram, pulse oximetry (SpO2), noninvasive 
arterial pressure, partial pressure of end-tidal CO2 (EtCO2) and 
neuromuscular monitoring by train-of-four (TOF) (TOF-Watch, 
Organon Ltd, Doublin, Ireland). The anesthetic depth was mon-
itored on the Bispectral Index (BIS VISTA Monitoring System, 
Aspect Medical Systems Inc, Norwood, MA, USA). A commer-
cial TCI system (Orchestra Base Primea, Fresenius Vial, Brezins, 
France) was used to maintain the effect-site concentration (Ce) 
of propofol according to Schnider’s pharmacokinetic model and 
that of remifentanil according to Minto’s model. 
Using a computer-generated randomization table, the pa-
tients were randomly allocated to one of two groups: dexme-
detomidine or remifentanil. The anesthesia was induced and 
maintained using a propofol TCI to maintain a BIS range of 45 
to 55. In the dexmedetomidine group, a bolus of fentanyl 1 μg/
kg and a loading of dexmedetomidine 0.5 μg/kg of loading for 
5 min and a continuous infusion of 0.5 μg/kg/hr administered. 
Labetalol 5 mg was administered as needed to maintain the HR 
and MBP within 20% of the preoperative resting values. In the 
remifentanil group, a Ce of remifentanil TCI was controlled to 
achieve a HR and MBP within 20% of the preoperative baseline 
values. After rocuronium 0.6 mg/kg was administered intrave-
nously, the patients were intubated using an endotracheal tube 
with an internal diameter of 7.5 mm (for males) or 6.5 mm (for 
females). A cuff was inflated to maintain the pressure between 
20−25 cmH2O with a manometer (Hi-LoTM Hand Pressure 
Gauge, VBM Medizintechnik GmbH, Sulz a.N., Baden-Würt-
temberg, Germany). Mechanical ventilation was maintained at a 
tidal volume of 8 ml/kg and EtCO2 of 35–45 mmHg, with an air/
oxygen mixture (FIO2: 0.5). 
The endoscopic surgeries were performed by a single surgeon 
following a standardized method, and the surgeon used soaking 
sponges with a 1 : 100,000 epinephrine solution as a vasocon-
strictor. 
Five minutes before the end of the surgery, the propofol was 
titrated to achieve the target BIS of 60. In the dexmedetomidine 
group, the dexmedetomidine infusion was stopped. In the remi-
fentanil group, the Ce of remifentanil was titrated to 2.0 ng/ml 
and was maintained until extubation. In both groups, after all 
surgical procedures were completed, the propofol was discon-
tinued and the fresh gas flow was adjusted to 10 L/min. There-
after, another anesthesiologist who was blinded to the patient 
groups performed the remaining anesthetic recovery processes. 
The anesthesiologist was blinded to the medications related to 
the study, as the syringe pumps were placed in a box and were 
invisible from the outside. The researcher in charge handled the 
medications and assisted the anesthesiologist. After confirming 
neuromuscular function by using the TOF response test, respi-
ration was assisted by manual ventilation. If the patients opened 
their eyes in response to verbal requests and if their respiration 
was adequate, the trachea was extubated following cuff defla-
tion. The patients in both groups were monitored while receiv-
ing 100% oxygen for 5 min, and were transferred to the post-
anesthetic care unit (PACU). If the patients asked for rescue 
analgesics and their postoperative pain score was above 5 points 
on the visual analogue scale (VAS), fentanyl 1 μg/kg was admin-
istered. 
After completion of the operation, the satisfaction with the 
visualization of the surgical field was assessed by the surgeon 
on a numeric rating scale (NRS) from 0 (= worst) to 10 (= best). 
The HR and MBP were recorded at the following times: T0; be-
fore induction, T1; before intubation, T2; after intubation, T3; 
after local injection, T4; 5 min after local injection, T5; 10 min 
after local injection, T6; 20 min after local injection, T7; 5 min 
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before end of operation, T8; end of operation, T9; extubation, 
T10; admission to the PACU. The recovery profiles, including 
the time to awakening (from discontinuation of propofol to eye 
opening in response to verbal command), the time to extubation 
(from discontinuation of propofol to extubation), the coughing 
reflex at extubation, and the respiration rate and sedation scale 
[8] in the PACU, were measured and recorded. The consump-
tion of anesthetic agents such as propofol, remifentanil, dexme-
detomidine and labetalol were recorded. The postoperative pain, 
as assessed on the VAS, postoperative nausea and vomiting, and 
administration of rescue medications were also recorded. Oc-
currence of other adverse events, such as upper airway obstruc-
tion, respiratory depression, emergence agitation, and postop-
erative awareness, were recorded. 
The sample size was calculated based on the previous finding 
that the VAS mean of surgical field was 3 ± 1.2 under propofol-
remifentanil [9] and that a difference in incidence of at least 30% 
would be clinically relevant. Thus, for α = 0.05, 18 patients per 
group were required. Assuming a loss of 10% in the follow-up peri-
od, a total sample size of 40 was needed to achieve a power of 80%. 
The statistical analyses were performed with SPSS 14.0 
(SPSS Inc., Chicago, IL, USA). The continuous and categori-
cal variables were analyzed using a t-test and Chi-square test, 
respectively. The MBP and HR were repeatedly measured, and 
were analyzed using a repeated measured one-way ANOVA. The 
nonparametric data were evaluated with an X2–test or Fisher’s 
exact test, as appropriate. A P value under 0.05 was considered 
significant. 
Results
Of the forty-three patients initially enrolled in the study, the 
data from thirty-nine patients were successfully analyzed. Four 
patients were dropped from the study for unrecognized upper 
respiratory infection, unrecognized arrhythmia, and conversion 
to open surgery. The patients’ characteristics did not differ be-
tween the two groups (Table 1). 
The median (interquartile range) of NRS for the visualization 
satisfaction was 7 (3) in the dexmedetomidine group and 7 (2) 
in the remifentanil group, and the difference between the two 
groups was not significantly different (P = 0.95). The satisfaction 
scores for the visualization of the surgical field in each patient 
group are shown in Fig. 1. 
There were no differences between the groups in terms of 
MBP (Fig. 2) or HR (Fig. 3). Eight patients in the dexmedetomi-
dine group received labetalol just once and one patient received 
labetalol twice. The consumption of propofol did not differ 
between the two groups. In the remifentanil group, the mean 
consumption of remifentanil was 775.2 ± 354.9 μg and in the 
dexmedetomidine group, the mean consumption of dexmedeto-
midine was 58.3 ± 23.4 μg. 
The recovery profiles are presented in Table 2. The extubation 
time was significantly shorter in the dexmedetomidine group 
(8.4 ± 1.8 min) than in the remifentanil group (11.9 ± 5.4 min) 
(P = 0.04). Except for the extubation time, the recovery profiles 
of the two groups were comparable at all observation periods. 
No adverse event occurred in either group.
Table 1. Demographic and Clinical Characteristics of Patients
Dexmedetomidine group (n = 18) Remifentanil group (n = 21) P value
Age (yr) 39.2 ± 12.5 36.2 ± 15.1 0.49
Gender (M/F) 14/7   9/9 0.32
ASA classification (I/II) 16/2 18/3 0.55
Height (cm) 168.6 ± 7.7 163.9 ± 14.3 0.24
Weight (kg) 66.7 ± 10.7 66.3 ± 12.6 0.91
Preoperative CT grade 7.0 ± 5.4 7.4 ± 5.5 0.22
Operation duration (min) 50.9 ± 26.7 64.8 ± 30.7 0.15
Anesthesia duration (min) 83.1± 27.7 96.1 ± 31.3 0.19
Propofol consumption (μg/kg/min) 122.1 ± 26.8 111.8 ± 19.9 0.23
 The values are presented as numbers or means ± SD. F: female, M: male, ASA: American Society of Anesthesiologists, CT: computed tomography.
Fig. 1. Satisfaction scores with visualization of the surgical field in each 
patient group. The difference between the two groups was not significant.
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Discussion
The main finding of this prospective double-blind random-
ized study was that intraoperative continuous dexmedetomidine 
infusions provide similar visualization of the surgical field and 
similar hemodynamic changes as remifentanil TCIs during ESS. 
In addition, the extubation time was shorter in the dexmedeto-
midine group, and other recovery profiles were statistically com-
parable. 
As the visualization of the surgical field is directly connected 
to the postoperative outcomes, the reduction of surgical bleed-
ing has been a major concern of otolaryngologists and anes-
thesiologists [2-4]. In previous studies, the visualization of the 
surgical field was founded to be directly correlated with the HR 
[10,11]. In particular, remifentanil was found to provide bet-
ter visualization of the surgical field, suggesting that this short-
acting opioid agent could reduce the HR and MBP immediately 
and effectively [12]. Thus, the continuous infusion of remifent-
anil has become a reliable strategy for the superior visualization 
of the surgical field in ESS [5]. 
Similarly to remifentanil, dexmedetomidine has been shown 
to have positive effects on the visualization of the surgical field 
in several ESS-related studies [6,13,14]. This improvement may 
be caused by the peripheral vasoconstrictive effect of the α2-
agonist. However, in existing ESS-related studies, the patients in 
the placebo group had a significantly higher HR than those in 
the dexmedetomidine group. It is preferable for the visualization 
of the surgical field to be achieved through reduction of the HR 
rather than through vasoconstriction. The present study set lim-
its for HR and MBP, and demonstrated similar hemodynamic 
changes in the two groups. 
To minimize the degree to which the severity and extension 
of the disease affect the bleeding, we estimated the preoperative 
Lund-Mackay CT score of the patients. The radiologic scoring 
system is part of the Lund-Mackay staging system and is used 
more widely than symptom scores and endoscopic scores. As the 
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Fig. 2. Comparison of changes in mean blood pressure between dex-
medetomidine group and remifentanil group. T0: before induction, 
T1: before intubation, T2: after intubation, T3: after local injection, 
T4: 5 min after local injection, T5: 10 min after local injection, T6: 20 
min after local injection, T7: 5 min before end of operation, T8: end of 
operation, T9: extubation, T10: admission to the PACU. 
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Fig. 3. Comparison of changes in heart rate between dexmedetomidine 
group and remifentanil group. T0: before induction, T1: before 
intubation, T2: after intubation, T3: after local injection, T4: 5 min after 
local injection, T5: 10 min after local injection, T6: 20 min after local 
injection, T7: 5 min before end of operation, T8: end of operation, T9: 
extubation, T10: admission to the PACU.
Table 2. Recovery Profiles of Patients 
Dexmedetomidine group (n = 18) Remifentanil group (n = 21) P value
Awake time (min) 7.1 ± 2.4 9.4 ± 5.3 0.17
Extubation time (min) 8.4 ± 1.8 11.9 ± 5.4 0.04
Respiratory rate in PACU (breaths/min) 14.7 ± 4.3 14.5 ± 4.3 0.85
Sedation scale in PACU 2 (1) 2 (1) 0.84
Postoperative pain score (VAS) 2 (2) 3 (2) 0.14
Incidence of PONV (%) 2 (11.1) 2 (9.5) 0.87
The values are presented as means ± SD or numbers (IQR or %). Awake time: from discontinuation of propofol to eye opening in response to verbal 
command, Extubation time: from discontinuation of propfol to extubation, PACU: postanesthetic care unit, IQR: interquartile range, VAS: visual 
analog score, PONV: postoperative nausea vomiting. 
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interpretation of CT scans does not require radiology training 
and is unambiguous, results can be expressed as simple numeric 
scores. As a result, this method has been shown to present high 
interobserver reliability [15]. The patients with higher Lund-
Mackay preoperative scores presented more risks of complica-
tions [7]. The scores were not significantly different between the 
two groups in this study. As there was only a small number of 
patients with high Lund-Mackey preoperative scores in our re-
sults, it is difficult to clarify the effect of this score on the visual-
ization of the ESS surgical field. Further study is needed to better 
understand the contribution of this score to the visualization of 
the surgical field.
The vasoconstrictive effect of intravenous dexmedetomi-
dine has been widely demonstrated in animal models [16,17]. 
Moreover, experimental research has provide evidence that 
intravenous dexmedetomidine has a vasoconstrictive effect on 
the human arterial and venous system [18,19]. However, there 
is a lack of direct evidence for the fact that intravenous dexme-
detomidine contracts the peripheral vessels directly and reduces 
surgical bleeding during actual operations. Intravenous dexme-
detomidine appears to reduce surgical bleeding and to improve 
the visualization of the surgical field in ESS only. 
Although dexmedetomidine has an analgesic effect, its an-
algesic property is weaker than that of remifentanil [20]. In the 
present study, the patients in the dexmedetomidine group were 
administered fentanyl and dexmedetomidine as analgesic agents. 
It is uncertain whether 1 μg/kg of fentanyl can provide sufficient 
analgesia in the induction period. If tachycardia or hypertension 
occurred afterwards, labetalol was administered to maintain the 
HR and MBP within 20% of the preoperative resting values. It 
is unclear whether this administration of labelatol could have 
influenced the local vasoconstriction in the nasal mucosa. How-
ever, the labetalol administration could not have had any signifi-
cant effect on the present result, as the vascularity of the nasal 
polypoid tissue is sparse [21], and labetalol has a weak blocking 
potency for the α1 - adrenergic receptor. [22]
In the present study, the continuous infusion of dexmedeto-
midine presented similar recovery profiles to remifentanil TCIs. 
There have been several reports of recovery profiles after the 
administration of intravenous dexmedetomidine during general 
anesthesia. Most studies demonstrated that the perioperative 
use of dexmedetomidine can reduce the postoperative opioid 
consumption, pain intensity, and need for antiemetic therapy 
[23,24]. Furthermore, there has been report that the use of intra-
venous dexmedetomidine in ESS caused less emergence agita-
tion and improved the quality of recovery [25]. In this study, we 
discontinued the dexmedetomidine five minutes before the end 
of the surgery, and the remifentanil directly after extubation. The 
comparison of the recovery profiles between the two agents is 
less precise due to the difference in discontinuation times. Those 
results supporting the favorable recovery effects of dexmedeto-
midine, which are comparable to those of remifentanil, indicate 
that the perioperative use of dexmedetomidine is a good option 
to guarantee the smooth emergence of high risk patients.
The limitations of this study should be mentioned. First, 
while the patients who received remifentanil TCIs served as 
a positive control group, the study did not include a placebo 
group, which would have provide a useful contrast with the dex-
medetomidine effect. Second, it was hard to titrate the remifent-
anil and dexmedetomidine to equipotent analgesic doses, as two 
agents have different pharmacologic properties. 
In conclusion, the present study showed that continuous dex-
medetomidine infusions provide a similar visualization of the 
surgical field to remifentanil TCIs in patients undergoing ESS. 
Furthermore, dexmedetomidine allows for comparably hemo-
dynamic stability and faster recovery than remifentanil TCI. 
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